The Center for Vaccine Development (CVD) develops new vaccines for emerging infectious diseases of pandemic importance by directly transferring its technology to LMIC-based vaccine producers without the involvement of multinational pharma companies. With this model, the CVD successfully developed several coronavirus vaccine technologies for the world’s poor. This led to the production and delivery of two recombinant protein SARS-CoV-2 (COVID-19) vaccines, CORBEVAX (with Biological E) in India and INDOVAC (with BioFarma) in Indonesia, with almost 100 million low-cost doses successfully administered to children and adults. We continue to prepare for future variants of the virus and for other coronaviruses that could spill over from animals into humans by employing both recombinant protein and mRNA vaccine technologies.
Vaccines
- SARS-Cov-2 (Covid-19)
- Thimmaraju et al. — A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2 — Vaccines
- Hotez et al. — From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access — Expert Review of Vaccines
- Hirsch et al. — Heterologous prime-pull mucosal vaccination with an adjuvanted RBD vaccine elicits robust IgA production and protects against SARS-CoV-2 — Frontiers in Immunology
- MERS
- Almutairi et al. — Characteristic profiling of CHO-cell expressed MERS-CoV RBD-Fc — International Journal of Biological Macromolecules
- SARS
- Tools
- Thimmaraju et al. — Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins — Viruses
